Gene

AUTS2

activator of transcription and developmental regulator AUTS2

Explore in graph →CI-GENE-00021490HGNC:14262 ENSG00000158321 NCBI 26053 Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AUTS2 Fusion1
(prognostic)	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID12838 The PAX5::AUTS2 represents a rare primary oncogenic driver in B-lymphoblastic Leukemia/lymphoma (B-ALL). An international cohort of 50 patients—including 16 previously reported cases—was assembled, w… (full text at CIViC) PMID 39702796 · Caye-Eude et al., 2025 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (8)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved8 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
RAD51B Associated Mixed Cancers (MSK, NPJ Breast Cancer 2021) mixed_msk_tcga_2021	unmapped	Ssm	1	4	25%

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

PAX5::AUTS2 childhood B-ALL: a relapse-prone genetic subtype with frequent central nervous system involvement and a poor outcome.
· Leukemia · 2025 · PMID 39702796 · validated civic_curation pubmed